Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$7.48B
sum of reported positions
Reported positions
301
Changes vs prior quarter
296
60 new · 37 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 314 measured positions in 8 quarters, the typical new or larger position finished −0.9 pts against the S&P 500 and 47% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 1.96M | $294M | 3.9% | |
| 673K | $292M | 3.9% | |
| 2.15M | $208M | 2.8% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $6.05B | $7.48B |
| Positions | 278 | 301 |
| Biggest line | — | Guardant Health 4% |
| 415K |
| $203M |
| 2.7% |
| 1.25M | $146M | 2.0% |
| 68K | $136M | 1.8% |
| 491K | $132M | 1.8% |
| 599K | $130M | 1.7% |
| 107K | $125M | 1.7% |
| 103K | $117M | 1.6% |
| 126K | $117M | 1.6% |
| 2.11M | $116M | 1.6% |
| 880K | $105M | 1.4% |
| 339K | $101M | 1.3% |
| 6.25M | $98.1M | 1.3% |
| 611K | $93.5M | 1.2% |
| 536K | $90.6M | 1.2% |
| 307K | $89.8M | 1.2% |
| 342K | $89M | 1.2% |
| 252K | $85.7M | 1.1% |
| 728K | $83.9M | 1.1% |
| 1.38M | $80.2M | 1.1% |
| 58K | $79.7M | 1.1% |
| 499K | $79.4M | 1.1% |
| 186K | $79.3M | 1.1% |
Avalyn Pharma (AVLN)
1.38M shares
Remitly (RELY)
1.33M shares
TD Synnex (SNX)
101K shares
Oruka Therapeutics (ORKA)
240K shares
Spyre Therapeutics (SYRE)
202K shares
Black Hills Corporation (BKH)
230K shares
NXP Semiconductors (NXPI)
56K shares
Achieve Life Sciences (ACHV)
2.22M shares
Kailera Therapeutics (KLRA)
617K shares
Tango Therapeutics (TNGX)
400K shares
Exxon Mobil (XOM)
83K shares
Coreweave (CRWV)
99K shares
Adlai Nortye Group (ANL)
719K shares
Cisco (CSCO)
67K shares
Kardigan (KARD)
300K shares
Inhibrx Biosciences (INBX)
62K shares
Kodiak Gas Services, Inc. (KGS)
33K shares
Ideaya Biosciences (IDYA)
65K shares
IBM (IBM)
8,493 shares
Advanced Energy (AEIS)
5,448 shares
Applied Materials (AMAT)
2,722 shares
CSX Corporation (CSX)
26K shares
Broadridge Financial Solutions (BR)
7,964 shares
Shift4 (FOUR)
11K shares
Thomson Reuters (TRI)
6,081 shares
